Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Parsabiv

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

- PMLiVE

NICE will take central role in UK’s value-based pricing system

DH confirms role of cost-effectiveness watchdog in drug reimbursement plans from 2014

- PMLiVE

Amgen says viral melanoma therapy clears phase III trial

OncoVex demonstrates durable response in skin cancer patients

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

- PMLiVE

Discount convinces NICE to uphold recommendation for Novartis’ Xolair

Asthma drug now also available for children

- PMLiVE

NICE recommends BMS-Pfizer’s Eliquis to prevent stroke

Joins Xarelto and Pradaxa anticoagulants as potential warfarin replacement

- PMLiVE

NICE set to turn down Lilly’s lung cancer drug Alimta

Draft guidance doesn't recommend medicine's use as type of maintenance therapy

- PMLiVE

NICE recommends test to support choice of breast cancer treatment

Genomic Health’s Oncotype DX could avoid over-treatment using chemotherapy

Novartis building

Novartis’ Jakavi turned down by NICE for blood cancer

UK cost-effectiveness watchdog concerned about 'uncertainties' in data in draft guidance

- PMLiVE

UCB-Amgen pull development of drug to heal fractures

But romosozumab remains on course in postmenopausal osteoporosis

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links